ELCC 2019 | I-O monotherapy for advanced NSCLC

Martin Reck

Martin Reck, MD, PhD, from Lung Clinic Grosshansdorf, Grosshansdorf, Germany, discusses the use of immuno-oncology agent monotherapy for the treatment of stage IV non-small cell lung cancer (NSCLC), referencing the results for pembrolizumab in the KEYNOTE-024 and KEYNOTE-042 trials. Speaking from the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Prof. Reck discusses the challenges faced in this field.

Share this video